CiLostAzol for pReventIon of Recurrent sTroke in Africa

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1100 participants.

Also called NCT06919835

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06919835
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Ghana (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06919835. Randomized; triple masking; primary purpose prevention. Start 2027-01-01 (anticipated); primary completion 2029-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CiLostAzol for pReventIon of Recurrent sTroke in Africa
Acronym
CLARITY-Africa
Condition
Stroke
Intervention (Drug)
Cilostazol 100 mg
Lead sponsor
Northern California Institute of Research and Education (class: other)

Record details

Record id
cardio:ct-nct06919835
Content hash
b40b677999cc7f88cce37156f67c50f8757e83cc6937128f22a2b24c43203dc2